Sublingual Methadone for the Management of Cancer Breakthrough Pain

AHS Cancer Control Alberta

Status and phase

Completed

Phase 1

Conditions

Cancer

Pain

Treatments

Drug: Methadone

Study type

Interventional

Funder types

Other

Identifiers

NCT00125294

Calgary Health Region

17208

Details and patient eligibility

About

A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.

Full description

This is a dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

> 18 years of age
Experiences episodes of breakthrough pain which respond to opioid therapy
Controlled baseline pain
Cognitive status sufficient for accurate completion of assessment form
Willing to provide written informed consent
Ability to hold a volume of 1 cc of water under the tongue for 5 minutes

Exclusion criteria

Currently or has received methadone during the previous week
Recent history of substance abuse
Severe respiratory impairment or other contraindications to opioids
Recently received therapies that had the potential to alter pain intensity or response to analgesics
Symptomatic anemia